PP088 The case fatality rate of COVID-19 infection in non-small cell lung cancer

ESMO Open

article

Y.J. Jung¹  S.H. Park¹  H.A. Jung¹  J-M. Sun¹  S-H. Lee¹  J.S. Ahn¹  M-J. Ahn¹ 

[1] Hematology-Oncology, Samsung Medical Center

关键词: COVID-19 Outbreak;    Omicron Variant;    NSCLC;   

DOI  :  10.1016/j.esmoop.2022.100696

学科分类：社会科学、人文和艺术（综合）

来源: BMJ Publishing Group

【 摘 要 】

Background: In the outbreak of COVID-19, the case fatality rate was higher, especiallyin advanced cancer patients. The Omicron variant was well known that had hightransmissibility but a lower risk of mortality. It has not been revealed whether thecurrent systemic treatment could be retained or not in advanced non-small cell lungcancer (NSCLC) patients with a COVID-19 infection. We investigated the case fatalityrate of a COVID-19 infection and the effect of COVID-19 infection on the currentsystemic treatments in advanced NSCLC patients.Methods: We retrospectively reviewed the medical record of NSCLC patients whowere diagnosed with COVID-19 infection at the Samsung Medical Center between2020 and 2022. The case fatality rate and risk factors for case fatality rate wereinvestigated.Results: Among 1,072 NSCLC patients who were diagnosis with COVID-19 infection,570 patients who were cured after surgery, and 143 patients had stable disease afterconcurrent chemo-radiotherapy. Among 452 advanced NSCLC patients, 387 patientsreceived systemic treatment in palliative setting. Of them, 188 patients who receivedtargeted therapy, 111 patients received cytotoxic chemotherapy, 69 patients receivedimmunotherapy +/- chemotherapy, and 19 patients received the systemic treatmentof clinical trial. Among them, 94.6% of patients (338 of 387) continued their systemictreatment after the COVID-19 infection. Only one patient discontinued their treatment due to complication of COVID-19 infection and 18 patients changed their systemic treatment due to disease progression. The case fatality rate was 3.8% (17 of452) in advanced NSCLC patients. The risk factor of the case fatality rate was old age(75 years), history of previous lung radiotherapy, current cytotoxic chemotherapy,and underlying lung disease (interstitial lung disease or chronic obstructive pulmonarydisease).Conclusions: In the Omicron wave, majority of advanced NSCLC patients continuedsystemic treatment and had low case fatality rate compared to other variants.However, patients with risk factor such as old age (75 years), history of previouslung radiotherapy, current cytotoxic chemotherapy, and underlying lung disease needcareful management.

【 授权许可】

CC BY|CC BY-NC-ND